Nanotherapeutics Overcoming the Blood-Brain Barrier for Glioblastoma Treatment
Glioblastoma (GBM) is the most common malignant primary brain tumor with a poor prognosis. The current standard treatment regimen represented by temozolomide/radiotherapy has an average survival time of 14.6 months, while the 5-year survival rate is still less than 5%. New therapeutics are still hig...
Enregistré dans:
| Auteurs principaux: | , , , , |
|---|---|
| Format: | article |
| Langue: | EN |
| Publié: |
Frontiers Media S.A.
2021
|
| Sujets: | |
| Accès en ligne: | https://doaj.org/article/f9e438306a1a47058f9d9880affffa4e |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|